APLS

Apellis Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 2/10
Apellis Pharmaceuticals sales and earnings growth
APLS Growth
Good
  • Revenue Y/Y↑ 42.46%
  • EPS Y/Y↑ 159.22%
  • FCF Y/Y↑ 545.44%
Apellis Pharmaceuticals gross and profit margin trends
APLS Profitability
Good
  • Gross margin ↑ 90.20%
  • EPS margin↑ 12.10%
  • ROIC 5Y↑ -84.23%
Apellis Pharmaceuticals net debt vs free cash flow
APLS Risk
Good
  • Debt / Equity↓ 1.1
  • Debt / FCF↓ 1.8
  • Interest coverage↓ 4.1

Apellis Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.

↗ More Biotechnology stocks